Pooled analysis of single-dose oritavancin in the treatment of acute bacterial skin and skin-structure infections caused by Gram-positive pathogens, including a large patient subset with methicillin-resistant Staphylococcus aureus.

Journal Article (Clinical Trial, Phase III;Journal Article;Multicenter Study)

Oritavancin is a lipoglycopeptide antibiotic with bactericidal activity against Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA). The phase 3 studies SOLO I and SOLO II demonstrated comparable efficacy and safety of a single dose of oritavancin compared with 7-10 days of twice-daily vancomycin in adults with acute bacterial skin and skin-structure infections (ABSSSIs). The present analysis assessed clinical responses by pathogen at 48-72 h and at study days 14-24 in SOLO patients within the pooled data set. Of the 1959 patients in the pooled SOLO studies, 1067 had at least one baseline Gram-positive pathogen and 405 had MRSA. Clinical response rates were similar for oritavancin- and vancomycin-treated patients by pathogen, including Staphylococcus aureus with or without the Panton-Valentine leukocidin (pvl) gene and from different clonal complexes, and were similar for pathogens within each treatment group. Oritavancin exhibited potent in vitro activity against all baseline pathogens, with MIC90 values (minimum inhibitory concentration required to inhibit 90% of the isolates) of 0.12 µg/mL for Staphylococcus  aureus, 0.25 µg/mL for Streptococcus pyogenes and 0.06 µg/mL for Enterococcus faecalis. Whereas both oritavancin and vancomycin achieved similarly high rates of clinical response by pathogen, including methicillin-susceptible and -resistant Staphylococcus aureus, oritavancin provides a single-dose alternative to 7-10 days of twice-daily vancomycin to treat ABSSSIs.

Full Text

Duke Authors

Cited Authors

  • Corey, GR; Arhin, FF; Wikler, MA; Sahm, DF; Kreiswirth, BN; Mediavilla, JR; Good, S; Fiset, C; Jiang, H; Moeck, G; Kabler, H; Green, S; O'Riordan, W; SOLO I, SOLO II Investigators,

Published Date

  • November 2016

Published In

Volume / Issue

  • 48 / 5

Start / End Page

  • 528 - 534

PubMed ID

  • 27665522

Electronic International Standard Serial Number (EISSN)

  • 1872-7913

Digital Object Identifier (DOI)

  • 10.1016/j.ijantimicag.2016.07.019


  • eng

Conference Location

  • Netherlands